Small molecule therapeutic developer Morphic, based on research at Harvard Medical School, has boosted its initial public offering from $90m to nearly $104m.

US-based integrin drug developer Morphic Holding, which emerged out of research at Harvard University’s Medical School, closed its initial public offering at approximately $104m yesterday. The company had floated on the Nasdaq Global Market in a $90m IPO last week, pricing 6 million shares at $15.00 each. The shares closed at $18.00 on their first…

The rest of this content is only accessible to Global University Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.